No Data
89bio to Present 48-Week Data From ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
PDF Version -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage b
89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald
89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald
RBC Capital Remains a Hold on 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.